Richard van Zyl-Smit (University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa) kindly took the time to speak with us about maximising the benefit of inhaler therapy and recent development being made in this field.
- What are the major unmet needs in the use of inhaled therapies for the control of asthma? (0:15)
- How can we help patients optimise their inhaler technique? (0:55)
- How can we maximise the benefits of inhaler therapy over 24 hours? (1:46)
- Which asthma patients are most likely to benefit from once daily single inhaler triple therapy? (2:39)
- What have been the most exciting recent developments in inhaler therapy? (3:49)
Speaker disclosure: Richard van Zyl-Smith has conducted clinical research trials for Novartis, AstraZeneca, Takeda, Merck, Almirall, Boehringer Ingelheim, Sanofi, Teva, Perl, Pfizer, Roche, GSK and Genetech. He has also received honoraria for academic talks from, Aspen, Pfizer, AstraZeneca, Novartis, Cipla, MSD, Roche, Jannsen, Boehringer Ingelheim and participated in advisory boards for GSK, Pfizer, AstraZeneca, Novartis, MSD and Roche.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ERS International Congress 2020
Share this Video
Related Videos In Asthma
Whitney Stevens, AAAAI 2021: Treatment of Aspirin-Exacerbated Respiratory Disease (AERD)
It was a pleasure to speak with Professor Whitney Stevens (Northwestern University Feinberg School of Medicine, Chicago, IL, US) around aspirin desensitisation in aspirin-exacerbated respiratory disease. ‘Aspirin desensitization for AERD in 2020: An update from the AERD work group.’ was presented at the American Academy of Allergy, Asthma & Immunology Virtual Annual Meeting, February 26-March […]
Klaus Rabe, AAAAI 2021 – The Efficacy of Dupilumab in GINA-Defined Difficult To-Treat Type 2 Asthma Patients (Part 2)
Dr Klaus Rabe (Lung Clinic Großhansdorf and The University of Kiel, Germany) spoke with touchRESPIRATORY around his post-hoc analysis of the LIBERTY ASTHMA QUEST study (Clinical Trial Identifier: NCT02414854). The abstract ‘Dupilumab Efficacy in GINA-Defined Difficult To-Treat Type 2 Asthma Patients in the LIBERTY ASTHMA QUEST Study.’ (ABSTRACT NUMBER: 183) was presented at the American […]
Klaus Rabe, AAAAI 2021 – The Efficacy of Dupilumab in GINA-Defined Difficult To-Treat Type 2 Asthma Patients (Part 1)
It was a pleasure to speak with Dr Klaus Rabe (Lung Clinic Großhansdorf and The University of Kiel, Germany) around the rationale for the use of dupilumab in GINA-defined difficult to-treat type 2 asthma patients (Clinical Trial Identifier: NCT02414854). The abstract ‘Dupilumab Efficacy in GINA-Defined Difficult To-Treat Type 2 Asthma Patients in the LIBERTY ASTHMA QUEST […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!